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differences in fractional anisotropy (FA) between groups.Results: The neu-
ropsychological assessment did not show an influence of ApoE4 on mea-
sures of memory or attention. Structural analyses with VBM and DTI did
not reveal any significant differences in gray matter and white matter vol-
ume or in FA between groups. In contrast to the neuropsychological and
structural findings, there was an effect of APOE-ε4 on functional activation
patterns during episodic memory associative encoding. Compared to the ho-
mozygote APOE-ε3 group, APOE-ε4 carriers showed reduced task-induced
activation in dorsolateral prefrontal cortex bilaterally and in the left parietal
cortex. Conclusions: These results suggest that the APOE-ε4 genotype af-
fects neuronal function in young adults but not micro- and macrostructure,
as detectable with VBM and TBSS. These findings are relevant to the ques-
tion of potential preclinical disease-driving factors, providing a rationale for
further studies assessing functional neuronal aberration as a possible inde-
pendent risk factor for the development of subsequent neurodegeneration
at older age.
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Background: Apolipoprotein E (APOE) genotype is the most significant
genetic variant associated with late-onset Alzheimer’s disease (AD) suscep-
tibility and pathological features [1]. However, the role of APOE in very
early prodromal stages of AD is not well understood. The new ADNI cate-
gory of early amnestic mild cognitive impairment (E-MCI) provides an op-
portunity to evaluate the role of APOE-ε4 genotype on psychometric
performance, amyloid deposition and neurodegeneration in patients with
very mild clinical impairments. Methods: Baseline pre-processed AV-45
PET scans [2], 3TMRI scans [3], APOE genotype [4] and other quantitative
phenotypes were downloaded from the ADNI website. Only participants
categorized as E-MCI (n ¼ 139) at baseline from ADNI-GO/2 were in-
cluded. MRI scans were processed using VBM, as previously described
[5]. AV-45 scans were co-registered to the concurrent MRI and normalized
to MNI space using parameters generated from MRI segmentation. Differ-
ences between APOE-ε4 allele positive and negative participants in AV-45
standardized uptake on a voxel-wise basis were assessed using a two-sample
t-test using SPM8. Region of interest (ROI) data was extracted from MRI
and AV-45 scans using MarsBaR. Neuropsychological performance, cogni-
tive complaints, and ROI data were compared between ε4 positive and neg-
ative participants using independent-samples t-tests (SPSS 19.0). Results:
Approximately 42% of the E-MCI participants (n ¼ 139) were APOE-ε4
positive (n ¼ 59; 2 ε2ε4, 48 ε3ε4, 9 ε4ε4; Table 1). The ε4 positive E-
MCI group showed lower performance on memory and global cognitive
measures, but a trend toward fewer cognitive complaints, than APOE-ε4
negative participants (n ¼ 80; 9 ε2ε3, 71 ε3ε3). On AV-45 PET, ε4 was as-
sociated with increased amyloid deposition, particularly in frontal and me-
dial parietal lobar regions (Figure 1A; P<0.05 FWE, k¼50). Similarly, ROI
analyses indicated greater amyloid deposition in the frontal lobes of ε4 pos-
itive E-MCI participants (Figure 1B; P<0.001). By contrast, the presence of
ε4 was not associated with greater hippocampal atrophy in this initial sam-
ple of E-MCI participants (Figure 1C). Conclusions: In E-MCI, APOE-ε4
genotypes are associated with greater amyloid deposition and cognitive
changes, but not hippocampal neurodegeneration. References: [1] Corder
(1993); [2] Jagust (2010); [3] Jack (2010); [4] Saykin (2010); [5] Risacher
(2009).
Table 1
Demographics and neuropsychological test performance (Mean (SE)
ε4 negative ε4 positive P-value
n 80 59
Age (years) 71.97 (0.86) 70.81 (1.00) ns
Gender (M, F) 39, 41 37, 22 ns
Education (years) 15.96 (0.30) 15.73 (0.35) ns
Handedness (R, L) 71, 9 55, 4 ns
CDR-SBa 1.11 (0.08) 1.38 (0.09) 0.022
ADAS-Cog Totala, b 10.95 (0.53) 13.79 (0.61) 0.0007
RAVLT Totala 41.76 (1.03) 37.54 (1.20) 0.009
RAVLT Delayed Recalla 6.97 (0.42) 5.23 (0.49) 0.008
Trail-Making B-Aa, c 53.90 (4.86) 69.38 (5.65) 0.042
ECog Patient Total 20.41 (1.08) 17.88 (1.25) ns
ECog Informant Total 16.03 (1.11) 14.80 (1.29) ns
ECog-Mem Patient Total 5.95 (0.23) 5.83 (0.27) ns
ECog-Mem Informant Total 4.94 (0.28) 4.78 (0.33) ns
ECog-Lang Patient Total 5.23 (0.30) 4.46 (0.35) ns
ECog-Lang Informant Total 3.36 (0.33) 3.27 (0.38) ns
ECog-VS Patient Total 2.58 (0.27) 1.85 (0.32) ns
ECog-VS Informant Total 1.95 (0.24) 1.39 (0.28) ns
ECog-Exec Patient Total 6.66 (0.48) 5.75 (0.55) ns
ECog-Exec Informant Total 5.78 (0.50) 5.36 (0.58) ns
aAdjusted for age, gender, education, and handedness
bMissing data for 1 ε4 negative participant
cMissing data for 3 participants (2 ε4 negative, 1 ε4 positive)
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Background: Hippocampal sclerosis (HpScl) is defined by the dispro-
portionate neuronal loss compared to neurofibrillary tangle (NFT) accu-
mulation in the hippocampus. “Pure” HpScl is uncommon, but is
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